Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 1 Parkinson's papers of 21 | 0.91 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 11516
Sealed predictions
- MFSD1 in dopamine neurons, braak+0.49 (p 0.182) → -0.16 (p 0.689)receipt 11524
Swarm cases
receipt 11524: MFSD1 in dopamine neurons, braak
- power
- full sample +0.21 (p 0.408, n 18), 95% CI -0.29 to +0.61. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.24 (p 0.337, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.27 (p 0.273, n 18). could be the mix.
- skeptic
- leave-one-out range +0.10 to +0.32, sign flips 0; without severely affected donors +0.21 (p 0.408, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.67 (p 0.0022, n 18) vs +0.21 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MFSD1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MFSD1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.30 p 0.286 (needs p < 1.9e-4)
Receipts
loading the receipts